Handelen Exicure, Inc. - XCUR CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.09 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.030779% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | -0.013666% | ||||||||
| Tijd van overnight-tarief | 22:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Belangrijkste statistieken
| Prev. Close* | 1.41 |
| Open* | 1.38 |
| 1-Jaarlijkse Verandering* | 626.32% |
| Dagelijks bereik* | 1.38 - 1.52 |
| 52 wekelijks bereik | 0.63-10.16 |
| Weekgemiddelde volume (10 dagen) | 21.02K |
| Gemiddeld volume (3 maanden) | 4.96M |
| Marktkapitalisatie | 6.85M |
| P/E Ratio | -100.00K |
| Uitstaande Aandelen | 4.96M |
| Omzet | 9.17M |
| EPS | -9.35 |
| Dividend (opbrengst %) | N/A |
| Beta | 0.98 |
| Volgende inkomsten datum | Mar 23, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Feb 2, 2023 | 1.41 | 0.04 | 2.92% | 1.37 | 1.46 | 1.36 |
| Feb 1, 2023 | 1.36 | -0.03 | -2.16% | 1.39 | 1.39 | 1.35 |
| Jan 31, 2023 | 1.38 | 0.05 | 3.76% | 1.33 | 1.40 | 1.31 |
| Jan 30, 2023 | 1.35 | -0.04 | -2.88% | 1.39 | 1.39 | 1.30 |
| Jan 27, 2023 | 1.38 | 0.01 | 0.73% | 1.37 | 1.39 | 1.34 |
| Jan 26, 2023 | 1.36 | 0.01 | 0.74% | 1.35 | 1.41 | 1.27 |
| Jan 25, 2023 | 1.36 | -0.01 | -0.73% | 1.37 | 1.46 | 1.35 |
| Jan 24, 2023 | 1.40 | 0.03 | 2.19% | 1.37 | 1.42 | 1.36 |
| Jan 23, 2023 | 1.41 | -0.07 | -4.73% | 1.48 | 1.48 | 1.37 |
| Jan 20, 2023 | 1.43 | 0.09 | 6.72% | 1.34 | 1.46 | 1.31 |
| Jan 19, 2023 | 1.34 | 0.00 | 0.00% | 1.34 | 1.38 | 1.30 |
| Jan 18, 2023 | 1.37 | 0.07 | 5.38% | 1.30 | 1.47 | 1.26 |
| Jan 17, 2023 | 1.30 | 0.03 | 2.36% | 1.27 | 1.31 | 1.24 |
| Jan 13, 2023 | 1.22 | 0.04 | 3.39% | 1.18 | 1.30 | 1.18 |
| Jan 12, 2023 | 1.19 | -0.14 | -10.53% | 1.33 | 1.37 | 1.18 |
| Jan 11, 2023 | 1.40 | 0.06 | 4.48% | 1.34 | 1.43 | 1.34 |
| Jan 10, 2023 | 1.36 | 0.09 | 7.09% | 1.27 | 1.40 | 1.27 |
| Jan 9, 2023 | 1.32 | -0.11 | -7.69% | 1.43 | 1.44 | 1.26 |
| Jan 6, 2023 | 1.48 | 0.05 | 3.50% | 1.43 | 1.51 | 1.43 |
| Jan 5, 2023 | 1.46 | 0.01 | 0.69% | 1.45 | 1.54 | 1.35 |
Exicure, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Jaarlijks
- Per kwartaal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Totale inkomsten | 1.036 | 9.719 | 0.118 | 1.296 | 16.613 | -0.483 |
| Inkomsten | 1.036 | 9.719 | 0.118 | 1.296 | 16.613 | -0.483 |
| Totale bedrijfskosten | 17.198 | 21.154 | 21.937 | 27.913 | 42.049 | 62.066 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 3.539 | 7.046 | 7.818 | 8.573 | 9.955 | 13.087 |
| Onderzoek & Ontwikkeling | 13.659 | 14.108 | 14.119 | 19.34 | 32.094 | 48.979 |
| Bedrijfsresultaat | -16.162 | -11.435 | -21.819 | -26.617 | -25.436 | -62.549 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -0.724 | -0.795 | -0.672 | -0.065 | 0.446 | -1.542 |
| Overige, Netto | -0.055 | 0.191 | 0.078 | 0.379 | 0.322 | -0.011 |
| Netto inkomen voor belastingen | -16.941 | -12.039 | -22.413 | -26.303 | -24.668 | -64.102 |
| Netto inkomen na belastingen | -16.941 | -12.039 | -22.413 | -26.303 | -24.668 | -64.102 |
| Netto inkomen voor extra. Posten | -16.941 | -12.039 | -22.413 | -26.303 | -24.668 | -64.102 |
| Netto inkomen | -16.941 | -12.039 | -22.413 | -26.303 | -24.668 | -64.102 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -16.941 | -12.039 | -22.413 | -26.303 | -24.668 | -64.102 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -16.941 | -12.039 | -22.413 | -26.303 | -24.668 | -64.102 |
| Verwaterd Netto Inkomen | -16.941 | -12.039 | -22.413 | -26.303 | -24.668 | -64.102 |
| Verwaterd Gewogen Gemiddelde Aandelen | 1.3099 | 1.3099 | 1.37284 | 1.9222 | 2.9065 | 2.95362 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -12.9331 | -9.1908 | -16.3261 | -13.6838 | -8.4872 | -21.7029 |
| Verwaterde Genormaliseerde Winst per Aandeel | -12.9331 | -9.1908 | -16.3261 | -13.6838 | -8.4872 | -21.7029 |
| Totale buitengewone posten | 0 | 0 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Totale inkomsten | 0.997 | 0.079 | -3.677 | 2.118 | 2.565 |
| Inkomsten | 0.997 | 0.079 | -3.677 | 2.118 | 2.565 |
| Totale bedrijfskosten | 13.154 | 13.941 | 19.404 | 15.567 | 10.302 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 2.892 | 3.098 | 2.947 | 4.15 | 3.162 |
| Onderzoek & Ontwikkeling | 10.262 | 10.843 | 16.457 | 11.417 | 7.14 |
| Bedrijfsresultaat | -12.157 | -13.862 | -23.081 | -13.449 | -7.737 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -0.32 | -0.405 | -0.445 | -0.372 | -0.591 |
| Overige, Netto | 0 | -0.002 | -0.005 | -0.004 | -0.02 |
| Netto inkomen voor belastingen | -12.477 | -14.269 | -23.531 | -13.825 | -8.348 |
| Netto inkomen na belastingen | -12.477 | -14.269 | -23.531 | -13.825 | -8.348 |
| Netto inkomen voor extra. Posten | -12.477 | -14.269 | -23.531 | -13.825 | -8.348 |
| Netto inkomen | -12.477 | -14.269 | -23.531 | -13.825 | -8.348 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -12.477 | -14.269 | -23.531 | -13.825 | -8.348 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -12.477 | -14.269 | -23.531 | -13.825 | -8.348 |
| Verwaterd Netto Inkomen | -12.477 | -14.269 | -23.531 | -13.825 | -8.348 |
| Verwaterd Gewogen Gemiddelde Aandelen | 2.92812 | 2.93449 | 2.93654 | 3.01522 | 4.03093 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -4.2611 | -4.86252 | -8.01317 | -4.58507 | -2.07099 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Verwaterde Genormaliseerde Winst per Aandeel | -4.2611 | -4.86252 | -8.01317 | -4.58507 | -2.07099 |
- Jaarlijks
- Per kwartaal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Totaal vlottende activa | 20.041 | 27.638 | 27.663 | 112.776 | 86.322 | 43.666 |
| Geldmiddelen en kortetermijnbeleggingen | 19.623 | 25.764 | 26.268 | 110.786 | 82.08 | 39.141 |
| Geldmiddelen & Equivalenten | 19.623 | 25.764 | 26.268 | 48.46 | 33.262 | 34.644 |
| Totale Vorderingen, Netto | 0.015 | 0.03 | 0.013 | 0.271 | 0.011 | 0 |
| Accounts Receivable - Trade, Net | 0 | 0.013 | 0.003 | 0.035 | 0.011 | 0 |
| Prepaid Expenses | 0.403 | 1.844 | 1.382 | 1.014 | 4.231 | 3.247 |
| Total Assets | 20.576 | 28.987 | 28.756 | 115.263 | 100.444 | 64.868 |
| Property/Plant/Equipment, Total - Net | 0.503 | 1.317 | 1.061 | 2.455 | 12.729 | 11.877 |
| Property/Plant/Equipment, Total - Gross | 1.12 | 2.166 | 2.25 | 3.772 | 14.469 | 14.544 |
| Accumulated Depreciation, Total | -0.617 | -0.849 | -1.189 | -1.317 | -1.74 | -2.667 |
| Other Long Term Assets, Total | 0.032 | 0.032 | 0.032 | 0.032 | 1.393 | 9.325 |
| Total Current Liabilities | 12.158 | 3.356 | 2.043 | 31.087 | 13.734 | 34.067 |
| Accounts Payable | 0.509 | 1.049 | 0.5 | 1.814 | 1.866 | 3.413 |
| Accrued Expenses | 2.16 | 1.273 | 1.543 | 2.435 | 3.525 | 6.464 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 1.213 | 0 | 4.965 | 0 | 6.873 | |
| Other Current Liabilities, Total | 8.276 | 1.034 | 0 | 21.873 | 8.343 | 17.317 |
| Total Liabilities | 18.128 | 9.012 | 7.804 | 34.516 | 38.938 | 53.636 |
| Total Long Term Debt | 4.655 | 4.855 | 4.925 | 0 | 16.589 | 0 |
| Long Term Debt | 4.655 | 4.855 | 4.925 | 0 | 16.589 | 0 |
| Other Liabilities, Total | 1.315 | 0.801 | 0.836 | 3.429 | 8.615 | 19.569 |
| Total Equity | 2.448 | 19.975 | 20.952 | 80.747 | 61.506 | 11.232 |
| Preferred Stock - Non Redeemable, Net | 42.63 | 0 | 0 | |||
| Common Stock | 0 | 0.004 | 0.004 | 0.009 | 0.009 | 0.011 |
| Additional Paid-In Capital | -17.578 | 53.586 | 75.942 | 162.062 | 167.379 | 181.29 |
| Retained Earnings (Accumulated Deficit) | -22.604 | -33.615 | -54.994 | -81.297 | -105.965 | -170.067 |
| Total Liabilities & Shareholders’ Equity | 20.576 | 28.987 | 28.756 | 115.263 | 100.444 | 64.868 |
| Total Common Shares Outstanding | 1.18368 | 1.3099 | 1.47845 | 2.86869 | 2.92142 | 3.62574 |
| Korte Termijn Investeringen | 62.326 | 48.818 | 4.497 | |||
| Other Current Assets, Total | 0.705 | 1.278 | ||||
| Other Equity, Total | -0.027 | 0.083 | -0.002 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 73.987 | 60.647 | 64.147 | 43.666 | 29.182 |
| Geldmiddelen en kortetermijnbeleggingen | 67.436 | 56.059 | 60.838 | 39.141 | 26.384 |
| Geldmiddelen & Equivalenten | 34.296 | 42.587 | 51.885 | 34.644 | 23.89 |
| Korte Termijn Investeringen | 33.14 | 13.472 | 8.953 | 4.497 | 2.494 |
| Totale Vorderingen, Netto | 0.224 | 0.044 | 0.027 | 0 | |
| Accounts Receivable - Trade, Net | 0 | 0 | 0 | 0 | |
| Prepaid Expenses | 5.02 | 3.642 | 2.173 | 3.247 | 1.669 |
| Other Current Assets, Total | 1.307 | 0.902 | 1.109 | 1.278 | 1.129 |
| Total Assets | 87.948 | 74.467 | 77.9 | 64.868 | 41.896 |
| Property/Plant/Equipment, Total - Net | 12.535 | 12.383 | 12.288 | 11.877 | 11.393 |
| Property/Plant/Equipment, Total - Gross | 14.346 | 14.473 | 14.661 | 14.544 | 14.359 |
| Accumulated Depreciation, Total | -1.811 | -2.09 | -2.373 | -2.667 | -2.966 |
| Other Long Term Assets, Total | 1.426 | 1.437 | 1.465 | 9.325 | 1.321 |
| Total Current Liabilities | 12.763 | 12.745 | 21.98 | 34.067 | 21.361 |
| Accounts Payable | 2.976 | 2.25 | 2.485 | 3.413 | 1.918 |
| Accrued Expenses | 2.441 | 3.228 | 5.48 | 6.464 | 3.227 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 7.346 | 7.267 | 14.015 | 17.317 | 16.216 |
| Total Liabilities | 37.907 | 37.827 | 63.917 | 53.636 | 38.66 |
| Total Long Term Debt | 16.659 | 16.73 | 16.801 | 0 | 0 |
| Long Term Debt | 16.659 | 16.73 | 16.801 | 0 | |
| Other Liabilities, Total | 8.485 | 8.352 | 25.136 | 19.569 | 17.299 |
| Total Equity | 50.041 | 36.64 | 13.983 | 11.232 | 3.236 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.009 | 0.009 | 0.009 | 0.011 | 0.012 |
| Additional Paid-In Capital | 168.442 | 169.337 | 170.217 | 181.29 | 181.644 |
| Retained Earnings (Accumulated Deficit) | -118.442 | -132.711 | -156.242 | -170.067 | -178.415 |
| Other Equity, Total | 0.032 | 0.005 | -0.001 | -0.002 | -0.005 |
| Total Liabilities & Shareholders’ Equity | 87.948 | 74.467 | 77.9 | 64.868 | 41.896 |
| Total Common Shares Outstanding | 2.93283 | 2.93626 | 2.93666 | 3.62574 | 4.0931 |
| Current Port. of LT Debt/Capital Leases | 6.873 | 0 |
- Jaarlijks
- Per kwartaal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | -16.941 | -12.039 | -22.413 | -26.303 | -24.668 | -64.102 |
| Geldmiddelen uit Operationele Activiteiten | -5.05 | -19.789 | -19.487 | 1.317 | -39.27 | -34.819 |
| Geldmiddelen uit Operationele Activiteiten | 0.18 | 0.232 | 0.358 | 0.392 | 0.766 | 1.123 |
| Niet-Geldelijke Posten | 0.942 | 1.437 | 2.179 | 1.981 | 2.896 | 4.048 |
| Veranderingen in het Operationeel Kapitaal | 10.769 | -9.419 | 0.389 | 25.247 | -18.264 | 24.112 |
| Geldmiddelen uit Investeringsactiviteiten | -0.394 | -0.926 | -0.094 | -63.432 | 10.142 | 43.085 |
| Kapitaaluitgaven | -0.394 | -0.926 | -0.094 | -1.082 | -3.171 | -0.968 |
| Geldmiddelen uit Financieringsactiviteiten | 6.336 | 26.856 | 20.085 | 84.307 | 15.13 | 1.116 |
| Financiering van Cash Flow Posten | -0.147 | -3.699 | -1.957 | -6.518 | -0.711 | -1.125 |
| Uitgifte (Aflossing) van aandelen, netto | 0.483 | 31.556 | 22.042 | 90.825 | 3.34 | 12.241 |
| Uitgifte (Aflossing) van Schulden, Netto | 6 | -1.001 | 0 | 12.501 | -10 | |
| Nettowijziging in Geldmiddelen | 0.892 | 6.141 | 0.504 | 22.192 | -13.998 | 9.382 |
| Overige Cash Flow investeringsposten, Totaal | -62.35 | 13.313 | 44.053 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -12.477 | -26.746 | -50.277 | -64.102 | -8.348 |
| Cash From Operating Activities | -14.809 | -25.885 | -21.022 | -34.819 | -12.756 |
| Cash From Operating Activities | 0.263 | 0.546 | 0.829 | 1.123 | 0.302 |
| Non-Cash Items | 0.693 | 1.578 | 3.04 | 4.048 | 1.006 |
| Changes in Working Capital | -3.288 | -1.263 | 25.386 | 24.112 | -5.716 |
| Cash From Investing Activities | 15.297 | 34.533 | 38.977 | 43.085 | 1.995 |
| Capital Expenditures | -0.225 | -0.564 | -0.623 | -0.968 | -0.006 |
| Other Investing Cash Flow Items, Total | 15.522 | 35.097 | 39.6 | 44.053 | 2.001 |
| Cash From Financing Activities | 0.546 | 0.677 | 0.668 | 1.116 | -7.993 |
| Financing Cash Flow Items | 0 | 0 | -0.009 | -1.125 | -0.507 |
| Issuance (Retirement) of Stock, Net | 0.546 | 0.677 | 0.677 | 12.241 | 0.014 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | -10 | -7.5 |
| Net Change in Cash | 1.034 | 9.325 | 18.623 | 9.382 | -18.754 |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group +485000+
Handelaren
65000+
Actieve klanten per maand
$48000000+
Maandelijks beleggingsvolume
$28000000+
Probeer het nu Opgenomen per maand
Handelscalculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Handelscommissie
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Hefboom
20:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
Exicure, Inc. Company profile
Over Exicure, Inc.
Exicure, Inc. is een biotechnologiebedrijf in een klinische fase. Het bedrijf houdt zich bezig met de ontwikkeling van therapeutica voor neurologie, immuno-oncologie, ontstekingsziekten en andere genetische aandoeningen op basis van zijn sferisch nucleïnezuur (SNA) technologie. De Vennootschap ontwikkelt XCUR-FXN, een op sferisch nucleïnezuur (SNA) gebaseerde therapeutische kandidaat voor de behandeling van ataxie van Friedreich (FA). XCUR-FXN bevat dankzij zijn SNA-technologie meer dan één actieve oligonucleotide in één enkele SNA-molecule. De therapeutische kandidaat van de Vennootschap cavrotolimod (AST-008) is een toll-like receptor 9 (TLR9) agonist, ontworpen voor immuno-oncologische toepassingen, gebruik makend van haar SNA-technologie. AST-008 is in een Fase I b/II klinische studie bij patiënten met vergevorderde vaste tumoren. TLR9 agonisten binden aan en activeren TLR9.
| Industry: | Bio Therapeutic Drugs |
2430 N. Halsted St.
CHICAGO
ILLINOIS 60614
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 485.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen